Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icalcaprant DDI with Itraconazole in healthy subjects
NCT06722430Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of icalcaprant in major depressive disorder (MDD) and opioid withdrawal, sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration at 14 days, Time to Cmax at 14 days and 6 more. Started Nov 2024; status: completed.
02
Drugs
icalcaprant
03
Conditions
major depressive disorder (MDD)opioid withdrawal
Beyond the preview
Go deeper on NCT06722430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722430.